These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 3434494)
41. [Treatment of prostatic cancer with progestational agents]. Bouffioux C Acta Urol Belg; 1976 Oct; 44(4):336-53. PubMed ID: 1026071 [No Abstract] [Full Text] [Related]
42. [Does chemotherapy have a role in the treatment of prostatic cancer?]. Verbaeys A Acta Urol Belg; 1991; 59(4):53-4. PubMed ID: 1819203 [No Abstract] [Full Text] [Related]
43. Criteria for the evaluation of cytostatic chemotherapy. Dold U Int J Clin Pharmacol Biopharm; 1978 Feb; 16(2):68-71. PubMed ID: 631973 [TBL] [Abstract][Full Text] [Related]
44. [The future of chemotherapy of prostatic cancer]. Grillo-López AJ; Vélez-García E Bol Asoc Med P R; 1975 Nov; 67(11):327-30. PubMed ID: 1060454 [No Abstract] [Full Text] [Related]
46. Chemotherapy of advanced prostatic cancer. Evaluation of response parameters. Schmidt JD; Gibbons RP; Johnson DE; Prout GR; Scott WW; Murphy GP Urology; 1976 Jun; 7(6):602-10. PubMed ID: 936381 [TBL] [Abstract][Full Text] [Related]
47. Chemotherapy of advanced prostatic cancer. Murphy GP Rev Surg; 1977; 34(2):75-87. PubMed ID: 854703 [No Abstract] [Full Text] [Related]
48. Workshop on response criteria and evaluation of the stable disease category in carcinoma of the prostate, breast, and large bowel. Murphy GP Oncology; 1984; 41(1):64-7. PubMed ID: 6366679 [TBL] [Abstract][Full Text] [Related]
49. Response criteria for the prostate of the USA National Prostatic Cancer Project. Murphy GP; Slack NH Prostate; 1980; 1(3):375-82. PubMed ID: 7279807 [TBL] [Abstract][Full Text] [Related]
50. Phototube response evaluation. Hammond Iii HK Appl Opt; 1968 May; 7(5):985. PubMed ID: 20068723 [No Abstract] [Full Text] [Related]
51. [Treatment for hormone-refractory or relapsing prostatic cancer]. Hirao Y; Ozono S; Okajima E Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492 [TBL] [Abstract][Full Text] [Related]
52. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
53. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria]. Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494 [TBL] [Abstract][Full Text] [Related]
54. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
55. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187 [TBL] [Abstract][Full Text] [Related]
56. [Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy]. Akaza H; Usami M; Kotake T; Matsumura Y; Moriyama N; Imai K; Fuse H; Isaka S; Yamanaka H; Matsumoto K Hinyokika Kiyo; 1987 Jun; 33(6):894-904. PubMed ID: 3673839 [TBL] [Abstract][Full Text] [Related]